What is Nephros, Inc. (NEPH) stock price today?

Nephros, Inc. (NEPH) is currently trading at $3.53, up 7.29% today.

What is NEPH P/E ratio?

Nephros, Inc.'s P/E ratio is 22.84. This is near the market average.

What is NEPH return on equity (ROE)?

Nephros, Inc.'s return on equity (ROE) is 16.20%, indicating how efficiently the company generates profit from shareholders' equity. This is above the market average.

What is Nephros, Inc.'s market cap?

Nephros, Inc. has a market capitalization of $38.32M.

NASDAQ · Medical - Instruments & Supplies

Nephros, Inc. (NEPH) Stock

$3.53 +7.29% NASDAQ: NEPH Healthcare

Valuation

Metric	Value
Price	$3.53
Market Cap	$38.32M
P/E Ratio	22.84
P/B Ratio	3.33
P/S Ratio	1.92
EPS (TTM)	$0.11
52-Week High	$6.42
52-Week Low	$2.66
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	16.20%
ROA	11.01%
ROCE	13.21%
Gross Margin	5.26%
Operating Margin	5.26%
Net Margin	8.38%
Debt/Equity	0.07
Current Ratio	3.67

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$10.0M	$10.0M	$14.0M	$14.0M	$19.0M
Operating Profit	$-3.0M	$-4.0M	$-2.0M	$0	$1.0M
Net Profit	$-4.0M	$-7.0M	$-2.0M	$0	$1.0M
EPS	$-0.41	$-0.72	$-0.15	$0.01	$0.11
Op Margin	-31.8%	-43.5%	-11.2%	0.0%	6.1%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$18.0M	$11.0M	$12.0M	$11.0M	$14.0M
Total Liabilities	$3.0M	$2.0M	$4.0M	$3.0M	$3.0M
Cash	$7.0M	$4.0M	$4.0M	$4.0M	$5.0M
Borrowings	$1.0M	$1.0M	$2.0M	$1.0M	$1.0M

Latest News

Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET GlobeNewswire · Jul 20, 2026 Northland Securities Initiates Coverage on Nephros With Market Perform Rating, $4 Price Target MT Newswires · Jul 17, 2026 Nephros Announces Inclusion in the Russell Microcap® Index GlobeNewswire · Jul 6, 2026 Nephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action” GlobeNewswire · Jun 18, 2026 Nephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water GlobeNewswire · Jun 16, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-1.0M	$-3.0M	$1.0M	$0	$2.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$-1.0M	$-3.0M	$1.0M	$-1.0M	$2.0M
Free Cash Flow	$-1.0M	$-3.0M	$1.0M	$-1.0M	$2.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.99
EV / EBITDA	19.82
FCF Yield	-1.66%
Quick Ratio	2.71
Interest Coverage	1642.00
Return 1Y	3.68%
Return 3Y	161.43%
Return 5Y	-59.24%

Ownership

Insiders Held12.87%

Institutions Held49.09%

Institutions Float Held56.34%

Institutional Holder	Shares	Report Date
Wexford Capital LP	3,600,552	2026-03-31
Topline Capital Management, LLC	581,967	2026-03-31
Vanguard Capital Management LLC	198,643	2026-03-31
Cornerstone Capital, Inc.	128,700	2026-03-31
Bard Associates Inc.	121,202	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BEATHeartbeam, Inc.	$0.48	-1.74%	-0.84	$26.65M	0.00%
DXRDaxor Corporation	$10.71	+2.24%	5.90	$53.94M	0.00%
HOWLWerewolf Therapeutics, Inc.	$0.98	+7.65%	-1.26	$47.61M	0.00%
ICCCImmuCell Corporation	$9.80	+0.51%	115.25	$88.66M	0.00%
NRXPNRX Pharmaceuticals, Inc.	$2.85	-1.38%	-3.79	$123.39M	0.00%

About Nephros, Inc.

Nephros, Inc. is led by CEO Robert Banks, employs 31 people, headquartered in US, publicly traded since 2004.

Nephros, Inc. (NEPH) stock trades at $3.53 with a market capitalization of $38.32M. The stock is valued at a price-to-earnings (P/E) ratio of 22.84, price-to-book of 3.33, price-to-sales of 1.92. Over the past 52 weeks the stock has ranged between $2.66 and $6.42, and currently trades 45.0% below its 52-week high.

On profitability, Nephros, Inc. generates a return on equity (ROE) of 16.20%, above the typical market average, return on capital employed of 13.21%, an operating margin of 5.26%, a net profit margin of 8.38%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides